Apellis Pharmaceuticals, Inc. (APLS) Misses Q3 EPS by 31c

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) reported Q3 EPS of ($1.75), $0.31 worse than the analyst estimate of ($1.44). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $21.74 million.

For earnings history and earnings-related data on Apellis Pharmaceuticals, Inc. (APLS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• CoStar Group acquires Zonda for $800M, adding new home data